#FDA — FinScans

📈 Stocks

UniQure Soars as FDA Clears Huntington’s Therapy for US Filing

June 17, 2026 (11 days ago)

UniQure stock pops following FDA’s reversal allowing Huntington’s disease therapy AMT-130 to move toward US approval filing.

QURE

🌍 US Read More →

📊 ETF IBB 📉 Bearish

May 12, 2026 (47 days ago)

FDA Commissioner Marty Makary’s resignation throws the agency into turmoil, threatening drug approvals and pressuring biotech and healthcare stocks.

▼ FDA Commissioner Makary resigns

📅 Short 🌍 US Read More →

📈 Stocks XLV 📉 Bearish

May 8, 2026 (50 days ago)

FDA gridlock clouds drug approval timelines, pressuring healthcare stocks and ETFs like XLV and IBB.

▼ Escalating reports of FDA dysfunction deepen sector uncertainty.

📅 Short 🌍 US Read More →